Published in J Virol on August 01, 2001
The human candidate tumor suppressor gene HIC1 recruits CtBP through a degenerate GLDLSKK motif. Mol Cell Biol (2002) 1.34
Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc Natl Acad Sci U S A (2006) 1.33
Interaction of MEQ protein and C-terminal-binding protein is critical for induction of lymphomas by Marek's disease virus. Proc Natl Acad Sci U S A (2006) 1.29
Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog (2010) 1.27
Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A (2011) 1.18
CtBPs promote cell survival through the maintenance of mitotic fidelity. Mol Cell Biol (2009) 1.12
EBNA3C coactivation with EBNA2 requires a SUMO homology domain. J Virol (2004) 1.12
Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS One (2010) 1.10
BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res (2012) 1.10
Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog (2011) 1.07
Epstein-Barr virus nuclear protein EBNA3C residues critical for maintaining lymphoblastoid cell growth. Proc Natl Acad Sci U S A (2009) 1.07
EBNA-3B- and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J Virol (2006) 1.04
EBV-encoded EBNA-6 binds and targets MRS18-2 to the nucleus, resulting in the disruption of pRb-E2F1 complexes. Proc Natl Acad Sci U S A (2008) 1.01
Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines. PLoS Pathog (2013) 1.01
Epstein-Barr virus nuclear antigen (EBNA) 3A induces the expression of and interacts with a subset of chaperones and co-chaperones. J Gen Virol (2008) 1.00
Epstein-Barr virus nuclear protein 3C domains necessary for lymphoblastoid cell growth: interaction with RBP-Jkappa regulates TCL1. J Virol (2009) 0.98
Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A. Proc Natl Acad Sci U S A (2013) 0.96
Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (2010) 0.96
Transcriptional regulatory properties of Epstein-Barr virus nuclear antigen 3C are conserved in simian lymphocryptoviruses. J Virol (2003) 0.95
Downregulation of integrin receptor-signaling genes by Epstein-Barr virus EBNA 3C via promoter-proximal and -distal binding elements. J Virol (2012) 0.95
Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming. PLoS Pathog (2013) 0.95
EBV finds a polycomb-mediated, epigenetic solution to the problem of oncogenic stress responses triggered by infection. Front Genet (2013) 0.91
Inactivation of intergenic enhancers by EBNA3A initiates and maintains polycomb signatures across a chromatin domain encoding CXCL10 and CXCL9. PLoS Pathog (2013) 0.90
Epstein-Barr virus EBNA-3C is targeted to and regulates expression from the bidirectional LMP-1/2B promoter. J Virol (2006) 0.89
E2F1 mediated apoptosis induced by the DNA damage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathog (2012) 0.89
Biophysical and mutational analysis of the putative bZIP domain of Epstein-Barr virus EBNA 3C. J Virol (2004) 0.88
Epstein-Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes. Proc Natl Acad Sci U S A (2014) 0.83
EBV Persistence-Introducing the Virus. Curr Top Microbiol Immunol (2015) 0.82
Epigenetic regulation of the latency-associated region of Marek's disease virus in tumor-derived T-cell lines and primary lymphoma. J Virol (2011) 0.81
The EBNA3 family of Epstein-Barr virus nuclear proteins associates with the USP46/USP12 deubiquitination complexes to regulate lymphoblastoid cell line growth. PLoS Pathog (2015) 0.81
Latent Epstein-Barr virus can inhibit apoptosis in B cells by blocking the induction of NOXA expression. PLoS One (2011) 0.80
Epstein-Barr Virus Proteins EBNA3A and EBNA3C Together Induce Expression of the Oncogenic MicroRNA Cluster miR-221/miR-222 and Ablate Expression of Its Target p57KIP2. PLoS Pathog (2015) 0.80
Epstein-Barr virus nuclear antigen 3A protein regulates CDKN2B transcription via interaction with MIZ-1. Nucleic Acids Res (2014) 0.79
Complementary quantitative proteomics reveals that transcription factor AP-4 mediates E-box-dependent complex formation for transcriptional repression of HDM2. Mol Cell Proteomics (2009) 0.79
EBNA3C Directs Recruitment of RBPJ (CBF1) to Chromatin during the Process of Gene Repression in EBV Infected B Cells. PLoS Pathog (2016) 0.79
Epstein-Barr virus nuclear antigen 3A promotes cellular proliferation by repression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1. PLoS Pathog (2014) 0.79
Dissecting the contribution of EBNA3C domains important for EBV-induced B-cell growth and proliferation. Oncotarget (2015) 0.77
Role of EBNA-3 Family Proteins in EBV Associated B-cell Lymphomagenesis. Front Microbiol (2016) 0.76
Deregulation of the cell cycle machinery by Epstein-Barr virus nuclear antigen 3C. Future Virol (2009) 0.75
EBV Nuclear Antigen 3C Mediates Regulation of E2F6 to Inhibit E2F1 Transcription and Promote Cell Proliferation. PLoS Pathog (2016) 0.75
An essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation. PLoS Pathog (2017) 0.75
The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev (2000) 5.93
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol (1993) 4.05
The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J Biol Chem (1998) 3.67
Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Proc Natl Acad Sci U S A (1995) 3.28
Cloning and characterization of mCtBP2, a co-repressor that associates with basic Krüppel-like factor and other mammalian transcriptional regulators. EMBO J (1998) 3.06
Drosophila CtBP: a Hairy-interacting protein required for embryonic segmentation and hairy-mediated transcriptional repression. EMBO J (1998) 2.74
ZEB represses transcription through interaction with the corepressor CtBP. Proc Natl Acad Sci U S A (1999) 2.64
Interaction of short-range repressors with Drosophila CtBP in the embryo. Science (1998) 2.61
Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. J Virol (1995) 2.45
Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor. J Biol Chem (2001) 2.45
Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature (2000) 2.44
dCtBP mediates transcriptional repression by Knirps, Krüppel and Snail in the Drosophila embryo. EMBO J (1998) 2.22
C-Terminal binding protein is a transcriptional repressor that interacts with a specific class of vertebrate Polycomb proteins. Mol Cell Biol (1999) 1.97
Epstein-Barr virus nuclear antigen 3C is a transcriptional regulator. J Virol (1995) 1.92
Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol (1999) 1.92
Nuclear localization and cell cycle-specific expression of CtIP, a protein that associates with the BRCA1 tumor suppressor. J Biol Chem (2000) 1.86
Ikaros interactions with CtBP reveal a repression mechanism that is independent of histone deacetylase activity. J Biol Chem (2000) 1.81
A mechanism for Rb/p130-mediated transcription repression involving recruitment of the CtBP corepressor. Proc Natl Acad Sci U S A (1999) 1.80
Net, a negative Ras-switchable TCF, contains a second inhibition domain, the CID, that mediates repression through interactions with CtBP and de-acetylation. EMBO J (1999) 1.76
Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA. J Virol (1996) 1.71
Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J Biol Chem (1999) 1.57
Identification of CtBP1 and CtBP2 as corepressors of zinc finger-homeodomain factor deltaEF1. Mol Cell Biol (1999) 1.57
The carboxy-terminal region of adenovirus E1A activates transcription through targeting of a C-terminal binding protein-histone deacetylase complex. FEBS Lett (1998) 1.55
Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene (1996) 1.52
Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J Virol (1997) 1.49
Epstein-Barr virus nuclear antigen 3C is a powerful repressor of transcription when tethered to DNA. J Virol (1996) 1.41
Enhanced ras oncogene mediated cell transformation and tumorigenesis by adenovirus 2 mutants lacking the C-terminal region of E1a protein. Oncogene (1989) 1.40
Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene (2000) 1.36
Molecular cloning and characterization of a novel retinoblastoma-binding protein. Genomics (1998) 1.26
zfh-1, the Drosophila homologue of ZEB, is a transcriptional repressor that regulates somatic myogenesis. Mol Cell Biol (1999) 1.22
Structural determinants present in the C-terminal binding protein binding site of adenovirus early region 1A proteins. J Biol Chem (1998) 1.17
Growth factor induction by the adenovirus type 5 E1A 12S protein is required for immortalization of primary epithelial cells. Mol Cell Biol (1988) 1.07
Immortalization of primary epithelial cells requires first- and second-exon functions of adenovirus type 5 12S. J Virol (1992) 1.06
A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear:cytoplasmic shuttling defect. Oncogene (1998) 0.85
Tularemia as a biological weapon: medical and public health management. JAMA (2001) 13.23
The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry (1982) 10.83
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (2000) 8.45
Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.96
Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.06
Controlled trial of three different antismoking interventions in general practice. Br Med J (Clin Res Ed) (1984) 6.25
ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell (2001) 4.38
The psychiatric status of patients with the chronic fatigue syndrome. Br J Psychiatry (1990) 4.10
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell (1999) 4.04
Intra-aneurysmal thrombosis as a possible cause of delayed aneurysm rupture after flow-diversion treatment. AJNR Am J Neuroradiol (2010) 3.03
EBV gene expression in an NPC-related tumour. EMBO J (1989) 2.94
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet (2000) 2.69
p53 mutations in BRCA1-associated familial breast cancer. Lancet (1997) 2.69
Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J (1992) 2.45
A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome. EMBO J (2001) 2.22
Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line. Virology (1990) 2.17
Global Deterioration Scale (GDS). Psychopharmacol Bull (1988) 2.14
Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation (1990) 2.13
Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ (2008) 2.03
The clinical features of bipolar depression: a comparison with matched major depressive disorder patients. J Clin Psychiatry (2001) 1.97
Randomised controlled trial of effectiveness of Leicester hospital at home scheme compared with hospital care. BMJ (1999) 1.97
Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol (1999) 1.92
p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J (1991) 1.91
Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation. J Virol (1993) 1.82
Proposed factor structure of the Geriatric Depression Scale. Int Psychogeriatr (1991) 1.76
Development of guidelines to facilitate improved support of South Asian carers by primary health care teams. Qual Health Care (2001) 1.72
The Parental Bonding Instrument. A decade of research. Soc Psychiatry Psychiatr Epidemiol (1990) 1.63
Array-based DNA methylation profiling in follicular lymphoma. Leukemia (2009) 1.63
Economic evaluation of hospital at home versus hospital care: cost minimisation analysis of data from randomised controlled trial. BMJ (1999) 1.62
Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene (2007) 1.62
Generation of asymmetry during development. Segregation of type-specific proteins in Caulobacter. J Cell Biol (1979) 1.62
Experiments on hydraulic jumps in turbidity currents near a canyon-fan transition. Science (1989) 1.61
The life skills profile: a measure assessing function and disability in schizophrenia. Schizophr Bull (1989) 1.57
Prediction of ECT response: validation of a refined sign-based (CORE) system for defining melancholia. Br J Psychiatry (1996) 1.56
High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene (2000) 1.53
Parental characteristics in relation to depressive disorders. Br J Psychiatry (1979) 1.53
Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene (1996) 1.52
Reliability of long-term recall of participation in physical activity by middle-aged men and women. Am J Epidemiol (1991) 1.51
What is chronic fatigue syndrome? Heterogeneity within an international multicentre study. Aust N Z J Psychiatry (2001) 1.51
Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J Virol (1997) 1.49
Continuity and change in medical care for young adults with disabilities. J R Coll Physicians Lond (1987) 1.48
Viral infection and cancer. Lancet (1995) 1.45
Beliefs about outcomes for mental disorders: a comparative study of primary health practitioners and psychiatrists in Singapore. Singapore Med J (2000) 1.45
Effect of physiotherapy on sickness absence in industry: a comparative study. J Soc Occup Med (1991) 1.43
Respiratory symptoms and wheat flour exposure: a study of flour millers. Occup Med (Lond) (2000) 1.42
Personality as a vulnerability factor to depression. Br J Psychiatry (1991) 1.41
p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene (1998) 1.41
Epstein-Barr virus nuclear antigen 3C is a powerful repressor of transcription when tethered to DNA. J Virol (1996) 1.41
Dural arteriovenous fistula in association with heterotopic brain nodule in the transverse sinus. AJNR Am J Neuroradiol (1998) 1.40
Development of a scale to measure interpersonal sensitivity. Aust N Z J Psychiatry (1989) 1.40
Neural network subtyping of depression. Aust N Z J Psychiatry (1998) 1.39
Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol (2012) 1.38
'New' and 'old' antidepressants: all equal in the eyes of the lore? Br J Psychiatry (2001) 1.38
Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene (2000) 1.36
Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv Cancer Res (1991) 1.36
Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. J Antimicrob Chemother (1983) 1.34
Reassessment of selective agars and filtration techniques for isolation of Campylobacter species from faeces. Eur J Clin Microbiol Infect Dis (1988) 1.34
Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death. J Virol (2001) 1.34
Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines. Mol Carcinog (1991) 1.33
A systematic review of discharge arrangements for older people. Health Technol Assess (2002) 1.33
Cloning of developmentally regulated flagellin genes from Caulobacter crescentus via immunoprecipitation of polyribosomes. Proc Natl Acad Sci U S A (1982) 1.31
HPV16 E7 oncoprotein deregulates B-myb expression: correlation with targeting of p107/E2F complexes. EMBO J (1994) 1.28
Parental 'affectionless control' as an antecedent to adult depression. A risk factor delineated. Arch Gen Psychiatry (1983) 1.28
Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene (1999) 1.26
Possible determinants, correlates and consequences of high levels of anxiety in primiparous mothers. Psychol Med (1986) 1.26
Seasonal variation in depressive disorders and suicidal deaths in New South Wales. Br J Psychiatry (1982) 1.24
Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. Am J Psychiatry (1999) 1.23
Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J (1995) 1.23
A study of client-focused case management and consumer advocacy: the Community and Consumer Service Project. Aust N Z J Psychiatry (1999) 1.22
The context and potential of epigenetics in oncology. Br J Cancer (2009) 1.20
Cognitive function in depression: a distinct pattern of frontal impairment in melancholia? Psychol Med (1999) 1.20
p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene (2001) 1.20
Cranial venous outflow obstruction and pseudotumor Cerebri syndrome. Adv Tech Stand Neurosurg (2005) 1.18
Depression in general practice attenders. "Caseness", natural history and predictors of outcome. J Affect Disord (1986) 1.18
Isolation of Campylobacter: what are we missing? J Clin Pathol (1987) 1.16
Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis (2013) 1.16
Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res (2000) 1.14
Fluorescein dilaurate--tubeless test for pancreatic exocrine failure. Lancet (1982) 1.14
Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma. Leukemia (2004) 1.13
Life event scales for obstetric groups. J Psychosom Res (1983) 1.13
Can the chronic fatigue syndrome be defined by distinct clinical features? Psychol Med (1995) 1.13
Brief antenatal cognitive behaviour therapy group intervention for the prevention of postnatal depression and anxiety: a randomised controlled trial. J Affect Disord (2007) 1.13
Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. Cell Death Dis (2012) 1.13
Parental reports of depressives. An investigation of several explanations. J Affect Disord (1981) 1.08
The development of a measure of intimate bonds. Psychol Med (1988) 1.08
Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins. Mol Cell Biol (2000) 1.08
Apoptosis induced by TGF-beta 1 in Burkitt's lymphoma cells is caspase 8 dependent but is death receptor independent. J Immunol (2000) 1.08
Overactive bladder medicine and precise cognitive testing. Int J Clin Pract (2009) 1.07
The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer. Br J Cancer (2009) 1.06
Characterization of ethanol-inducible human liver N-nitrosodimethylamine demethylase. Biochemistry (1986) 1.04
Professional and non-professional intervention for highly anxious primiparous mothers. Br J Psychiatry (1985) 1.04
Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat. Mol Pharmacol (1986) 1.03
Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling. Oncogene (1993) 1.03